{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T06:04:58Z","timestamp":1732341898802,"version":"3.28.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"DOI":"10.7759\/cureus.74269","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T02:56:59Z","timestamp":1732330619000},"source":"Crossref","is-referenced-by-count":0,"title":["Gastrointestinal Stromal Tumor of the Rectum: Report of a Case With Long-Term Imatinib Treatment"],"prefix":"10.7759","author":[{"given":"Madhumita","family":"Tripathi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roli","family":"Purwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richie","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198309000-00001","article-title":"Gastric stromal tumors. Reappraisal of histogenesis","volume":"7","author":"Mazur MT","year":"1983","unstructured":"Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983, 7:507-19. 10.1097\/00000478-198309000-00001","journal-title":"Am J Surg Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/708596","article-title":"Gastrointestinal stromal tumors: molecular mechanisms and targeted therapies","volume":"2011","author":"Downs-Kelly E","year":"2011","unstructured":"Downs-Kelly E, Rubin BP. Gastrointestinal stromal tumors: molecular mechanisms and targeted therapies. Patholog Res Int. 2011, 2011:708596. 10.4061\/2011\/708596","journal-title":"Patholog Res Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota S","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y, et al.. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998, 279:577-80. 10.1126\/science.279.5350.577","journal-title":"Science"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010105","article-title":"GISTs with NTRK gene fusions: a clinicopathological, immunophenotypic, and molecular study","volume":"15","author":"Cao Z","year":"2022","unstructured":"Cao Z, Li J, Sun L, et al.. GISTs with NTRK gene fusions: a clinicopathological, immunophenotypic, and molecular study. Cancers (Basel). 2022, 15:105. 10.3390\/cancers15010105","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00649","article-title":"Efficacy of trametinib in neurofibromatosis type 1-associated gastrointestinal stromal tumors: a case report","author":"Fukuda M","year":"2024","unstructured":"Fukuda M, Mukohara T, Kuwata T, Sunami K, Naito Y. Efficacy of trametinib in neurofibromatosis type 1-associated gastrointestinal stromal tumors: a case report. JCO Precis Oncol. 2024, e2300649. 10.1200\/PO.23.00649","journal-title":"JCO Precis Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-006-3424-1","article-title":"Gastrointestinal stromal tumor of the rectum: an analysis of seven cases","volume":"37","author":"Baik SH","year":"2007","unstructured":"Baik SH, Kim NK, Lee CH, et al.. Gastrointestinal stromal tumor of the rectum: an analysis of seven cases. Surg Today. 2007, 37:455-9. 10.1007\/s00595-006-3424-1","journal-title":"Surg Today"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-1002","article-title":"Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study","volume":"24","author":"Ma GL","year":"2015","unstructured":"Ma GL, Murphy JD, Martinez ME, Sicklick JK. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev. 2015, 24:298-302. 10.1158\/1055-9965.EPI-14-1002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.18.3211","article-title":"Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins","volume":"18","author":"Plaat BE","year":"2000","unstructured":"Plaat BE, Hollema H, Molenaar WM, et al.. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol. 2000, 18:3211-20. 10.1200\/JCO.2000.18.18.3211","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri GD","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, et al.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002, 347:472-80. 10.1056\/NEJMoa020461","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1081\/cnv-120002485","article-title":"Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas","volume":"20","author":"Edmonson JH","year":"2002","unstructured":"Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest. 2002, 20:605-12. 10.1081\/cnv-120002485","journal-title":"Cancer Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido","volume":"17","author":"Balachandran VP","year":"2011","unstructured":"Balachandran VP, Cavnar MJ, Zeng S, et al.. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011, 17:1094-100. 10.1038\/nm.2438","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6087-9","article-title":"Rectal gastrointestinal stromal tumor (GIST) in the era of imatinib: organ preservation and improved oncologic outcome","volume":"24","author":"Cavnar MJ","year":"2017","unstructured":"Cavnar MJ, Wang L, Balachandran VP, et al.. Rectal gastrointestinal stromal tumor (GIST) in the era of imatinib: organ preservation and improved oncologic outcome. Ann Surg Oncol. 2017, 24:3972-80. 10.1245\/s10434-017-6087-9","journal-title":"Ann Surg Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0116","article-title":"NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors","volume":"8 Suppl 2","author":"Demetri GD","year":"2010","unstructured":"Demetri GD, von Mehren M, Antonescu CR, et al.. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010, 8 Suppl 2:S1-41; quiz S42-4. 10.6004\/jnccn.2010.0116","journal-title":"J Natl Compr Canc Netw"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.183.6.01831619","article-title":"CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings","volume":"183","author":"Choi H","year":"2004","unstructured":"Choi H, Charnsangavej C, de Castro Faria S, et al.. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004, 183:1619-28. 10.2214\/ajr.183.6.01831619","journal-title":"AJR Am J Roentgenol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1102\/1470-7330.2012.0013","article-title":"Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group","volume":"12","author":"Kalkmann J","year":"2012","unstructured":"Kalkmann J, Zeile M, Antoch G, et al.. Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. Cancer Imaging. 2012, 12:126-35. 10.1102\/1470-7330.2012.0013","journal-title":"Cancer Imaging"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.196642","article-title":"Early evaluation of response using (18)f-FDG PET influences management in gastrointestinal stromal tumor patients treated with neoadjuvant imatinib","volume":"59","author":"Farag S","year":"2018","unstructured":"Farag S, Geus-Oei LF, van der Graaf WT, et al.. Early evaluation of response using (18)f-FDG PET influences management in gastrointestinal stromal tumor patients treated with neoadjuvant imatinib. J Nucl Med. 2018, 59:194-6. 10.2967\/jnumed.117.196642","journal-title":"J Nucl Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.02","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-247. 10.1016\/j.ejca.2008.10.02","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000484102","article-title":"Long-term imatinib treatment for patients with unresectable or recurrent gastrointestinal stromal tumors","volume":"97","author":"Ogata K","year":"2018","unstructured":"Ogata K, Kimura A, Nakazawa N, et al.. Long-term imatinib treatment for patients with unresectable or recurrent gastrointestinal stromal tumors. Digestion. 2018, 97:20-5. 10.1159\/000484102","journal-title":"Digestion"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-007-0746-y","article-title":"Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202)","volume":"13","author":"Nishida T","year":"2008","unstructured":"Nishida T, Shirao K, Sawaki A, et al.. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol. 2008, 13:244-51. 10.1007\/s10147-007-0746-y","journal-title":"Int J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/235957-gastrointestinal-stromal-tumor-of-the-rectum-report-of-a-case-with-long-term-imatinib-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T02:57:01Z","timestamp":1732330621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/235957-gastrointestinal-stromal-tumor-of-the-rectum-report-of-a-case-with-long-term-imatinib-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.74269","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}